Systemic vasculitis: one year in review 2026

Clinical and Experimental Rheumatology 2026

View at publisher
Authors: Chiara Marvisi, Paolo Delvino, Federica Di Cianni, Francesco Ferro, Sara M. Monti, Michele Moretti, Francesco Muratore, Ludovica Pisapia, Caterina Ricordi, Antonello Sulis, Rosaria Talarico, Elena Treppo
+2 more Luca Quartuccio, Carlo Salvarani
DOI: 10.55563/clinexprheumatol/bdck2x
Cited by: 1

Abstract

Systemic vasculitides are rare, heterogeneous inflammatory diseases associated with significant morbidity due to vascular and end-organ damage.In 2025, major advances have refined pathogenic insights and therapeutic strategies across large-vessel vasculitis (LVV), ANCA-associated vasculitis (AAV), single-organ vasculitis, and cryoglobulinemic vasculitis (CV). Multi-omics and spatial transcriptomic approaches, imaging, and serological biomarkers are informing prognosis and management.Glucocorticoid minimisation remains a unifying therapeutic goal. Targeted therapies such as JAK inhibitors, avacopan and anti-IL-5/IL-5R agents have demonstrated efficacy and steroid-sparing effects in both trials and real-world studies. Together, these advances mark a transition toward precision, phenotype-driven management in systemic vasculitis.

Fields of Study & Subjects

Vasculitis and related conditions Systemic Sclerosis and Related Diseases Otitis Media and Relapsing Polychondritis

Publication details

Journal / source
Clinical and Experimental Rheumatology
Publisher
Clinical and Experimental Rheumatology
Volume
44
Issue
4
Pages
593–606
Publication date
27 February 2026
Language
EN